CPHI Pharma Awards 2025 reward Fujifilm, RezonBio and Esteve leaders
Winners at the ceremony in Frankfurt also included CNX Therapeutics, NunaBio, Evonik Industries and Corden Pharma.
List view / Grid view
Winners at the ceremony in Frankfurt also included CNX Therapeutics, NunaBio, Evonik Industries and Corden Pharma.
Strengthens its downstream process offering with the addition of JSR’s Amsphere Protein A resin technology.
The pharma company invested $445m to expand its Coppell site.
Regulator classifies former Catalent site as ‘official action indicated’, impacting biotech clients such as Regeneron.
Gains access to OTX-201, a preclinical CAR T therapy being developed to treat autoimmune diseases.
Gains US-based operations with its new Phoenix, Arizona injectable drug product manufacturing and packaging site.
The company will now put a total of $4.5 billion into the Virginia site, expanding its remit to include active pharmaceutical ingredients for cancer drugs.
Sets bioequivalence and active pharmaceutical ingredient (API) requirements for its new ANDA prioritisation programme.
Establishes Resource for AI Science in Europe and eyes frontier AI models and autonomous agentic AI for pharma.
The investment will cover CMO collaborations and a new manufacturing and quality hub in Hyderabad.
FDA approval for the idiopathic pulmonary fibrosis drug supported by the pharma company’s FIBRONEER phase III clinical trials.
He joins the US company with over two decades of experience in pharma operations, supply chain and manufacturing.
The study is one of three to start, along with those in hidradenitis suppurativa and radiographic axial spondyloarthritis.
Companies’ first-line ambitions for the antibody drug conjugate buoyed by the TROPION-Breast02 clinical trial.
This update includes sterile manufacturing, bio-manufacturing, cell line development and radiopharmaceuticals.